Reporting 2025 - Siegfried

Home / Investors / Reporting 2025

Reporting

Download our latest reports

Annual Report 2025

Full Annual Report

Progress Report

Lagebericht (DE)

Corporate Governance Report

Remuneration Report

Sustainability Report

Financial Report

Half-Year Report 2025

Find previous reports, results presentations, German translations and webcasts in our investors download center

Investors download center

Annual report 2025

Letter to the shareholders

For 2025, Siegfried reported a strong financial performance, delivering across all key financial metrics. Continued profitable growth was driven by disciplined execution and operational efficiency, despite ongoing macroeconomic volatility and currency headwinds. Execution of the EVOLVE⁺ strategy remains well on track, resulting in growing momentum in inbound customer inquiries and the strategic acquisition of high-quality small molecule drug substance capacity in the US.

Key figures 2025

Siegfried delivers strong profitability and continued growth

0.0

Net sales (in million CHF)

Net sales in 2025 reached CHF 1,327.8 million.
Increase: +2.6%

0.0

Core EBITDA (in million CHF)

Core EBITDA in 2025 reached CHF 312.3 million.
Increase: +9.3%

0.0

Core EBIT (in million CHF)

Core EBIT in 2025 reached CHF 217.5 million.
Increase: +8.3%

0.0

Core net profit (in million CHF)

Core net profit in 2025 amounts to CHF 162.1 million.
Increase: +2.0%

In conversation with the CEO

Chief Executive Officer Marcel Imwinkelried on Siegfried’s journey in 2025 and its priorities in the year to come.

Read the interview

The year 2025 in review

January: New leadership team members
Luca Dalla Torre and Stefan Randl join the Executive Committee as Chief Legal and Sustainability Officer and Chief Scientific Officer, respectively.

April: New leadership team member
Olesia Silateva joins the Executive Committee as Chief Human Resources Officer

April: Sustainable progress
Siegfried receives validation approval for near term and net zero greenhouse gas reduction targets by the Science Based Targets initiative

May: Drug products expansion
Siegfried announces further expansion of ophthalmic drug manufacturing site in El Masnou in addition to ongoing expansion of sterile ophthalmic ointments

August: New leadership team member
Peter Freisler joins the Executive Committee as Chief Business Officer

August: CFO of the year
Chief Financial Officer Reto Suter awarded CFO Forum Schweiz’s CFO of the Year in category “Swiss Performance Index® (SPI®) without SMI Expanded”

September: DINAMIQS facility opening
Siegfried DINAMIQS' inaugurates new cGMP manufacturing facility for viral vectors

December: Drug product expansions
Siegfried strengthens spray drying capabilities in Barberà del Vallès and expands fill-finish operations in Hameln